| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, Mass., April 16 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced the creation of the new position of Chief Scientific Officer and a newly constituted Scientific Advisory Board (SAB) of world class experts from both the biopharmaceutical industry and leading academic organizations.
GNS's first Chief Scientific Officer, Dr. James Collins, is Professor of Biomedical Engineering and University Professor at Boston University and co-director of Boston University's Center for Biodynamics. Collins is a MacArthur Fellow, an original Technology Review TR100 award recipient, a recipient of an NIH Director's Pioneer Award, and a Rhodes Scholar. Professor Collins will also co-chair GNS's Scientific Advisory Board. He is the founder and former CSO of Cellicon Biotechnologies, a leading systems biology company, and Afferent Corporation, a medical device company.
"Professor Collins' broad experience as a scientific leader in systems biology and the reverse-engineering of genetic networks makes him uniquely qualified to lead GNS's scientific efforts," said Colin Hill, President and Chief Executive Office of GNS.
"During the past year, GNS has made important advances in the validation of its technology," said Collins. "In addition to discovering drug mechanism of action and biomarkers used by its pharma partners in clinical development, GNS's formation of discovery alliances with leading academic clinics and its discovery of potential therapeutic targets ab initio from human data has established GNS as a unique computational biology company."
Supporting Collins in his new role as CSO of GNS is a newly constituted
Scientific Advisory Board that brings expertise in key areas that will be
invaluable in evolving GNS's discovery engine and advancing GNS's pipeline
of gene network based targets and diagnostics programs from discovery to
market. Members of the new SAB are leading pharmaceutical executives and
academic systems bi
'/>"/>
| SOURCE Gene Network Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |